E-067
Ethosuximide solution
1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
等级
certified reference material
特点
Snap-N-Spike®/Snap-N-Shoot®
包装
ampule of 1 mL
制造商/商品名称
Cerilliant®
浓度
1.0 mg/mL in methanol
包装形式
single component solution
储存温度
−20°C
SMILES字符串
CCC1(C)CC(=O)NC1=O
InChI
1S/C7H11NO2/c1-3-7(2)4-5(9)8-6(7)10/h3-4H2,1-2H3,(H,8,9,10)
InChI key
HAPOVYFOVVWLRS-UHFFFAOYSA-N
基因信息
human ... CACNA1G(8913), CACNA1H(8912), CACNA1I(8911)
一般描述
Ethosuximide is an anticonvulsant specifically used to treat absence seizures. This Snap-N-Spike® Reference Solution is suitable for LC/MS or GC/MS applications in clinical toxicology, forensic analysis, urine drug testing, or pharmaceutical research.
法律信息
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
警示用语：
Danger
危险分类
Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1
靶器官
Eyes
储存分类代码
3 - Flammable liquids
WGK
WGK 1
闪点(°F)
49.5 °F - closed cup
闪点(°C)
9.7 °C - closed cup
法规信息
危险化学品
此项目有
Susumu Ito et al.
Brain & development, 34(10), 829-833 (2012-03-06)
Benign myoclonic epilepsy in infancy (BMEI) is the youngest form of idiopathic generalized epilepsy, characterized by myoclonic seizures (MS) in the first three years of life in otherwise normal infants, and the lack of other seizure types except for rare
K Iu Sarkisova et al.
Zhurnal vysshei nervnoi deiatelnosti imeni I P Pavlova, 61(2), 227-235 (2011-06-17)
Antiabsence drug ethosuximide (300 mg/kg/day in drinking water for 17 days) produced an antidepressant effect (a decrease in immobility time in forced swimming test) only in WAG/Rij rats genetically predisposed to absence epilepsy only at age of 5 months when
Gholam Ali Hamidi et al.
European journal of pharmacology, 674(2-3), 260-264 (2011-12-03)
Neuropathic pain is caused by a lesion or disease of the somatosensory nervous system and treatment of neuropathic pain remains a challenge. The purpose of the present study was to examine the effect of ethosuximide, an anti-epileptic and relatively selective
Meng-Hsuan Hsiao et al.
Journal of controlled release : official journal of the Controlled Release Society, 161(3), 942-948 (2012-06-02)
Thermo-gelling injectable nanogels, with no burst release of loaded drug, were prepared by a simple route by combining self assembled nanocapsules of amphiphilically modified chitosan with glycerophosphate di-sodium salt and glycerol. The potential as a depot drug delivery system was
Gilles van Luijtelaar et al.
International journal of psychophysiology : official journal of the International Organization of Psychophysiology, 85(1), 49-54 (2011-09-29)
Recently it was established that early long lasting treatment with the anti-absence drug ethosuximide (ETX) delays the occurrence of absences and reduces depressive-like symptoms in a genetic model for absence epilepsy, rats of the WAG/Rij strain. Here it is investigated
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持